Home > Publications database > Quantification of HPV16 E7 Oncoproteins in Urine Specimens from Women with Cervical Intraepithelial Neoplasia. > print

001     291408
005     20241030150257.0
024 7 _ |a 10.3390/microorganisms12061205
|2 doi
024 7 _ |a pmid:38930587
|2 pmid
024 7 _ |a pmc:PMC11205804
|2 pmc
024 7 _ |a altmetric:164830076
|2 altmetric
037 _ _ |a DKFZ-2024-01382
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a Makioka, Daiki
|b 0
245 _ _ |a Quantification of HPV16 E7 Oncoproteins in Urine Specimens from Women with Cervical Intraepithelial Neoplasia.
260 _ _ |a Basel
|c 2024
|b MDPI
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1719835778_5816
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a We present the validity of using an ultrasensitive enzyme-linked immunosorbent assay (ELISA) for quantifying high-risk human papillomavirus (HPV) 16 E7 oncoproteins in urine specimens as a noninvasive method of analyzing the oncogenic activity of HPV. Some reports claim that the oncogenic activity of HPV is a more relevant clinical indicator than the presence of HPV DNA for estimating malignant potential. In the present study, urine containing HPV16 and related types were selected by uniplex E6/E7 polymerase chain reaction and classified according to the pathologic diagnosis of cervical intraepithelial neoplasia (CIN) in cervical biopsy specimens. Our ultrasensitive ELISA was able to detect attomole levels of HPV16 E7 oncoproteins, and it detected HPV16-positive SiHa cells at >500 cells/mL without detecting HPV18-positive cells. Our ELISA results showed E7 oncoproteins in 80% (4/5) of urine specimens from women with HPV16-positive CIN1, 71% (5/7) of urine specimens from CIN2 patients, and 38% (3/8) of urine specimens from CIN3 patients. Some urine specimens with undetectable E7 oncoproteins were thought to be negative for live HPV 16-positive cells or in an inactivated state of infection. These results provide the basis for assessing oncogenic activity by quantifying E7 oncoproteins in patient urine.
536 _ _ |a 314 - Immunologie und Krebs (POF4-314)
|0 G:(DE-HGF)POF4-314
|c POF4-314
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a E7 oncoprotein
|2 Other
650 _ 7 |a human papillomavirus
|2 Other
650 _ 7 |a noninvasive diagnosis
|2 Other
650 _ 7 |a ultrasensitive ELISA
|2 Other
650 _ 7 |a uniplex E6/E7 PCR
|2 Other
650 _ 7 |a urine
|2 Other
700 1 _ |a Inada, Mikio
|b 1
700 1 _ |a Awano, Masayuki
|b 2
700 1 _ |a Saito, Ema
|b 3
700 1 _ |a Shinoda, Takuya
|b 4
700 1 _ |a Abe, Satoko
|b 5
700 1 _ |a Yoshimura, Teruki
|b 6
700 1 _ |a Müller, Martin
|0 P:(DE-He78)47d2c5b8ee00ab8a0c16e14137427579
|b 7
|u dkfz
700 1 _ |a Sasagawa, Toshiyuki
|0 0000-0002-8480-844X
|b 8
700 1 _ |a Ito, Etsuro
|0 0000-0002-1877-6566
|b 9
773 _ _ |a 10.3390/microorganisms12061205
|g Vol. 12, no. 6, p. 1205 -
|0 PERI:(DE-600)2720891-6
|n 6
|p 1205
|t Microorganisms
|v 12
|y 2024
|x 2076-2607
856 4 _ |u https://inrepo02.dkfz.de/record/291408/files/microorganisms-12-01205.pdf
856 4 _ |u https://inrepo02.dkfz.de/record/291408/files/microorganisms-12-01205.pdf?subformat=pdfa
|x pdfa
856 4 _ |u https://inrepo02.dkfz.de/record/291408/files/cancers-16-00718-v2.pdf
856 4 _ |u https://inrepo02.dkfz.de/record/291408/files/cancers-16-00718-v2.pdf?subformat=pdfa
|x pdfa
909 C O |o oai:inrepo02.dkfz.de:291408
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)47d2c5b8ee00ab8a0c16e14137427579
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-314
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Immunologie und Krebs
|x 0
914 1 _ |y 2024
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MICROORGANISMS : 2022
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-04-12T15:01:16Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-04-12T15:01:16Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-04-12T15:01:16Z
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2023-04-12T15:01:16Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-08-26
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-26
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-08-26
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-08-26
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-08-26
920 1 _ |0 I:(DE-He78)D335-20160331
|k D335
|l Tumorvirus-spez. Vakzinierungsstrategie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)D335-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21